In July 2023, we changed our name from AACC (short for the American Association for Clinical Chemistry) to the Association for Diagnostics & Laboratory Medicine (ADLM). The following page links to resources that were written prior to the rebranding and/or mentions events that took place prior to the rebranding and that contain mentions of the association’s old name.
AACC continually tracks legislative and regulatory issues of importance to clinical laboratories and the clinical laboratory profession. This is a listing of AACC's 2013 comment letters. AACC commented on a wide range of topics to federal and state authorities.
Legislative issues
AACC endorsed Senate legislation reauthorization the federal newborn screening program
SEP.10.2013
AACC endorsed legislation supporting advances in newborn screening programs
MAY.07.2013
AACC urged congressional leaders to support federal funding for the National Children's Study
MAY.07.2013
AACC joined with the Friends of AHRQ in supporting the President's FY'14 budget request for AHRQ
APR.18.2013
APR.16.2013
MAR.18.2013
AACC objected to the adoption of a laboratory copayment
MAR.11.2013
AACC provided feedback to NCS regarding proposed Medicare edits
MAR.04.2013
AACC endorsed Senate legislation to repeal the medical device tax
FEB.26.2013
AACC endorsed legislation repealing the medical device excise tax
FEB.20.2013
FEB.04.2013
Regulatory issues
AUG.27.2013
AACC joined with other laboratory groups in opposing additional cuts in pathology services
AUG.23.2013
AUG.19.2013
JUL.26.2013
JUL.11.2013
AACC wrote to CMS express concerns about it was pricing the new molecular pathology codes
JUL.08.2013
AACC provided comments to CMS regarding changes to its PT rule
MAR.04.2013